Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program To Reinforce Significant Patient Benefits Demonstrated By Company’s Leading Contact Force Therapy

DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the BIOSENSE WEBSTER ADVANTAGESM Program, an outcomes-based, risk-sharing program for U.S. hospitals that reinforces the significant patient benefits demonstrated by the company’s THERMOCOOL SMARTTOUCH® Catheter. This is the first therapy approved by the U.S. Food and Drug Administration (FDA) to enable direct and real-time measurement of contact force during catheter ablation and the only integrated catheter in the world that can provide stability of contact force.1

Help employers find you! Check out all the jobs and post your resume.